These findings suggest that Puma inhibitors may have therapeutic potential for the treatment of these disorders.

On August 1, 2023, AstraZeneca has reached an agreement to pay $510 million to BMS to resolve patent lawsuit over its PD-L1 mAb Imfinzi (Durvalumab) and CTLA-4 mAb Imjudo (Tremelimumab).

On August 1, 2023, MyMD Pharmaceuticals announced that the oral Tumor Necrosis Factor-α (TNF-α) inhibitor MYMD-1 achieved statistically significant positive results in a Phase 2 randomized clinical trial (NCT05283486).

On July 31, 2023, Sumitomo Dainippon Pharma and Otsuka Pharmaceutical jointly announced that their two Phase III studies, DIAMOND 1 and DIAMOND 2, for ulotaront (SEP-363856) in the treatment of acute schizophrenia did not meet the primary endpoints.

In a recent study, researchers from Stanford University in the US have made a significant discovery in the field of cancer treatment.

On August 1, 2023, the official website of the Chinese Drug Evaluation Center (CDE) shows that the new drug application (NDA) for Zolbetuximab injection developed by Astellas has been accepted for review.

Dostarlimab is the first immunotherapy approved by the FDA to be used in combination with chemotherapy for the first-line treatment of this patient population.

A new study published in the journal Gut has revealed a potential new target on TAMs for cancer immunotherapy.

Checkpoint Therapeutics announced the long-term data obtained in its key study on the PD-L1 inhibitor cosibelimab for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).

Recently, a study has been published in The Lancet, which conducted a clinical trial comparing the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Yeast-like Candida albicans and Candida glabrata, as well as filamentous fungi from the Aspergillus genus, are primary causes of systemic fungal diseases for susceptible individuals. The emergence of multidrug-resistant Candida fungi, such as Candida auris, also presents a major global health challenge.

Betibeglogene autotemcel, also known as Lovotibeglogene autotemcel and marketed as ZYNTEGLO, is an intravenous injection developed by bluebird bio, Inc.